Safety and efficacy of 48 mm Xience Xpedition everolimus-eluting stent for the treatment of long coronary lesions.

Autor: Gautier A; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Hovasse T; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Arroyo D; Hôpital Fribourgeois, Service de Cardiologie, Fribourg, Suisse, Switzerland., Unterseeh T; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Garot P; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Champagne S; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Neylon A; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Sanguineti F; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Benamer H; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Chevalier B; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France., Lefèvre T; Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France.
Jazyk: angličtina
Zdroj: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2022 Aug; Vol. 100 (2), pp. 179-187. Date of Electronic Publication: 2022 May 27.
DOI: 10.1002/ccd.30249
Abstrakt: Introduction: Long drug-eluting stents may limit the issue of overlapping multiple stents when treating long coronary lesions.
Aim: The aim of the study was to assess the safety and efficacy of the 48 mm Xience Xpedition everolimus-eluting stent (48mm-EES) for the treatment of long coronary lesions, in an all-comer population.
Methods: Patients receiving at least one 48mm-EES were prospectively included from March 2014 to December 2018. The primary endpoint was target lesion failure (TLF), defined as a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization (TLR) at 1 year. The main secondary endpoint was the patient-oriented composite endpoint (POCE) defined as a composite of death, stroke, myocardial infarction, and reintervention.
Results: A total of 268 patients with 276 long coronary lesions, including 94 chronic total occlusions (CTO), were successfully treated using at least one 48mm-EES. The total stent length per lesion was 66 ± 22 mm. A single 48mm-EES was suitable to successfully treat the target lesion in 48% of cases (60% for non-CTO lesions). One-year follow-up rate was 96.3%. TLF occurred in 13 patients (5.3%), mainly driven by TLR (4.1%). Two cardiac death occurred (0.7%). POCE occurred in 30 patients (11.6%) mainly driven by repeat revascularization (9.7%). Definite stent thrombosis was observed in two patients (0.7%). No difference was observed in one-year outcomes between single 48mm-EES and multiple stents implantation as well as between CTO and non-CTO lesions.
Conclusion: The 48mm-EES is safe and effective to treat long coronary lesions, including CTOs, and provides attractive cost-effectiveness by limiting multiple stenting.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: